Contraception and Family Planning — MCQs

Contraception and Family Planning Indian Medical PG Practice Questions and MCQs

Question 251: What is the pregnancy rate with a female condom compared to a male condom?

A. Lower than a male condom
B. Higher than a male condom (Correct Answer)
C. Same as a male condom
D. Zero

Explanation: The efficacy of contraceptive methods is measured by the **Pearl Index** (number of pregnancies per 100 woman-years of use). When comparing barrier methods, the female condom (FC1/FC2) consistently shows a higher failure rate than the male latex condom. ### **Explanation of the Correct Answer** The pregnancy rate for the female condom is **higher** than the male condom due to differences in both "perfect use" and "typical use" failure rates: * **Male Condom:** Typical use failure rate is approximately **13-18%**. * **Female Condom:** Typical use failure rate is approximately **21-27%**. The higher failure rate in female condoms is attributed to technical difficulties in insertion, the risk of the penis being inserted between the vaginal wall and the condom, and the potential for the external ring to be pushed into the vagina during intercourse. ### **Analysis of Incorrect Options** * **A & C:** These are incorrect because clinical trials and WHO data consistently rank the female condom as less effective than the male condom. * **D:** No contraceptive method (except total abstinence) has a zero pregnancy rate. Even surgical sterilization has a small failure rate. ### **High-Yield Clinical Pearls for NEET-PG** * **Material:** Most modern female condoms (FC2) are made of **nitrile** (synthetic rubber), making them safe for those with latex allergies and compatible with oil-based lubricants. * **Dual Protection:** Like male condoms, female condoms provide "dual protection" against both pregnancy and **STIs/HIV**. * **Pearl Index:** Always remember that the most effective reversible method is the **LARC** (Long-Acting Reversible Contraception) like IUCDs or Implants, while barrier methods have the highest typical-use failure rates among modern methods. * **Unique Feature:** The female condom can be inserted up to **8 hours** before intercourse, unlike the male condom which requires an erect penis and immediate application.

Question 252: In combined oral contraceptive pills, the contraceptive effect of the estrogenic component is primarily related to which of the following?

A. Conversion of ethinyl estradiol to mestranol
B. Suppression of cervical mucus secretion
C. Suppression of growth hormone-releasing hormone secretion
D. Suppression of follicle-stimulating hormone (FSH) secretion (Correct Answer)

Explanation: ### Explanation The primary mechanism of action for Combined Oral Contraceptive Pills (COCPs) is the suppression of ovulation through a negative feedback loop on the hypothalamic-pituitary-ovarian axis. **Why Option D is Correct:** The **estrogenic component** (most commonly Ethinyl Estradiol) primarily acts by **suppressing Follicle-Stimulating Hormone (FSH)** secretion from the anterior pituitary. By inhibiting FSH, the recruitment and maturation of ovarian follicles are prevented, ensuring no dominant follicle develops. While the progestogen component is responsible for suppressing the LH surge (preventing ovulation), estrogen provides stability to the endometrium and synergistically inhibits FSH to prevent follicular escape. **Why the Other Options are Incorrect:** * **Option A:** This is biochemically backward. Mestranol is a prodrug that must be **converted to ethinyl estradiol** in the liver to become biologically active. * **Option B:** This is the primary role of the **progestogen component**, not estrogen. Progestogens make the cervical mucus thick, tenacious, and cellular, which acts as a barrier to sperm penetration. * **Option C:** COCPs act on **Gonadotropin-Releasing Hormone (GnRH)** in the hypothalamus and FSH/LH in the pituitary, not Growth Hormone-Releasing Hormone (GHRH), which regulates growth hormone. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Mechanism of COCP:** Inhibition of ovulation (Estrogen $\rightarrow$ $\downarrow$FSH; Progestogen $\rightarrow$ $\downarrow$LH surge). * **Most Common Estrogen:** Ethinyl Estradiol (EE). * **Most Common Progestogen:** Levonorgestrel (2nd Gen) or Desogestrel/Gestodene (3rd Gen). * **Non-contraceptive benefits:** Reduced risk of ovarian and endometrial cancers (protective effect lasts years after discontinuation), reduced PID, and improvement in dysmenorrhea. * **Absolute Contraindications:** Undiagnosed vaginal bleeding, history of thromboembolism (DVT/PE), smokers >35 years, and estrogen-dependent tumors (Breast CA).

Question 253: What is the recommended dose of mifepristone for medical abortion?

A. 600 mg (Correct Answer)
B. 200 mg
C. 400 mg
D. 100 mg

Explanation: **Explanation:** The correct answer is **600 mg** because this is the dosage currently recommended under the **MTP (Medical Termination of Pregnancy) Act of India** for medical abortion up to 63 days (9 weeks) of gestation. **Medical Rationale:** Mifepristone is an anti-progestational agent that binds to progesterone receptors with high affinity, leading to decidual breakdown, cervical softening, and increased uterine sensitivity to prostaglandins. While clinical trials (and WHO guidelines) suggest that 200 mg is equally effective, the **statutory dose** prescribed by the Drug Controller General of India (DCGI) and the MTP Act remains **600 mg orally**, followed 48 hours later by 400 mcg of Misoprostol (either orally or vaginally). **Analysis of Options:** * **Option A (600 mg):** The standard legal and academic answer for NEET-PG based on Indian national guidelines. * **Option B (200 mg):** Though globally recommended by the WHO as the "evidence-based" dose to reduce cost and side effects, it is not the standard answer for Indian competitive exams unless "WHO guidelines" are specifically mentioned. * **Option C & D (400 mg / 100 mg):** These are sub-therapeutic or incorrect doses for the purpose of medical abortion. 400 mcg is, however, the standard dose for the second drug, Misoprostol. **High-Yield Clinical Pearls for NEET-PG:** * **MTP Act Limit:** Medical abortion is permitted up to **9 weeks (63 days)** of gestation. * **Mechanism:** Mifepristone (Antiprogestin) + Misoprostol (PGE1 analogue). * **Emergency Contraception:** A single dose of **10 mg** mifepristone can be used as an emergency contraceptive. * **Other uses:** Mifepristone is also used in the management of Cushing’s syndrome and uterine fibroids.

Question 254: All of the following statements regarding the mechanism of action of combined oral contraceptive drugs are TRUE, EXCEPT:

A. Progestins prevent ovulation by suppressing LH release.
B. Progestins cause thickening of cervical mucus and prevent sperm passage.
C. Estrogen modifies tubal and uterine contractions and prevents fertilization. (Correct Answer)
D. Estrogen makes the endometrium hyperproliferative and hypersecretory, preventing implantation.

Explanation: ### Explanation The Combined Oral Contraceptive Pill (COCP) works through a synergistic mechanism involving both estrogen and progestin. **Why Option C is the correct answer (The False Statement):** While estrogen does have minor effects on tubal motility, its primary role in COCPs is the **suppression of Follicle Stimulating Hormone (FSH)**, which inhibits follicular development. The modification of tubal and uterine contractions to prevent fertilization is not a primary or clinically significant mechanism of action for the estrogen component of COCPs. **Analysis of other options:** * **Option A:** Progestins provide the primary contraceptive effect by suppressing **Luteinizing Hormone (LH)**. This prevents the mid-cycle LH surge, thereby inhibiting ovulation. * **Option B:** Progestins cause the cervical mucus to become thick, viscid, and scanty (hostile), which physically prevents sperm penetration into the upper reproductive tract. * **Option D:** Estrogen and Progestin together alter the endometrium. While estrogen typically promotes proliferation, the dominant progestogenic effect in COCPs leads to an **asynchronous/atrophic endometrium** (not hyperproliferative) that is unfavorable for implantation. *Note: In the context of this question, the description of endometrial alteration is a recognized mechanism, whereas Option C is fundamentally incorrect regarding the primary prevention of fertilization.* **High-Yield NEET-PG Pearls:** * **Primary Mechanism:** Inhibition of ovulation (Progestin suppresses LH; Estrogen suppresses FSH). * **Most Common Side Effect:** Breakthrough bleeding (especially with low-dose pills). * **Beneficial Effects:** Reduced risk of Ovarian and Endometrial cancers (protective effect persists for years after discontinuation). * **Absolute Contraindications:** Undiagnosed vaginal bleeding, history of Thromboembolism (VTE), Estrogen-dependent tumors (Breast CA), and smokers >35 years old.

Question 255: Thromboembolism is primarily associated with which component of oral contraceptive pills (OCPs)?

A. Progesterone
B. Estrogen (Correct Answer)
C. Iron
D. Follicle Stimulating Hormone (FSH)

Explanation: **Explanation:** The correct answer is **Estrogen**. **1. Why Estrogen is Correct:** The association between Combined Oral Contraceptive Pills (COCPs) and venous thromboembolism (VTE) is primarily attributed to the **Estrogen** component (usually Ethinyl Estradiol). Estrogen exerts a pro-thrombotic effect by altering the hepatic synthesis of clotting factors. Specifically, it: * **Increases** levels of clotting factors II, VII, IX, and X. * **Decreases** levels of natural anticoagulants like Antithrombin III and Protein S. * **Increases** platelet aggregation. This shift in the balance toward a hypercoagulable state significantly increases the risk of deep vein thrombosis (DVT) and pulmonary embolism. **2. Why Other Options are Incorrect:** * **Progesterone:** While some third-generation progestins (e.g., Desogestrel) may slightly modulate the risk when combined with estrogen, the primary causative agent for the hypercoagulable state is estrogen. Progesterone-only pills (POPs) are generally considered safe for patients with a history of VTE. * **Iron:** Iron is often added to the 7-day placebo phase of OCP packs (e.g., Mala-N) to prevent iron-deficiency anemia; it has no effect on the coagulation cascade. * **FSH:** FSH is a gonadotropin produced by the pituitary, not a component of OCPs. OCPs actually work by *suppressing* FSH and LH. **3. NEET-PG High-Yield Pearls:** * **Dose-Dependency:** The risk of VTE is dose-dependent; modern "low-dose" pills (<50 µg Ethinyl Estradiol) have a lower risk than older formulations. * **Contraindications:** History of VTE, smoking in women >35 years, and migraine with aura are absolute contraindications for Estrogen-containing OCPs (WHO Eligibility Criteria Category 4). * **Surgery:** OCPs should ideally be stopped **4 weeks prior** to major elective surgery to reduce postoperative VTE risk.

Question 256: Regarding the removal of a cervical cap, what is true?

A. The cervical cap should be left in place for the entire cycle length.
B. The cervical cap must be left in place for at least 8 hours after intercourse. (Correct Answer)
C. The cervical cap can be removed immediately, followed by vaginal douching.
D. The cervical cap should be left until the next menstruation starts.

Explanation: **Explanation:** The cervical cap is a barrier method of contraception that fits snugly over the cervix. To ensure maximum efficacy, it must be left in place for at least **6 to 8 hours after the last act of intercourse**. This duration is critical because it allows the spermicide used with the cap to effectively immobilize and kill any sperm remaining in the vaginal vault, preventing them from ascending into the cervical canal. **Analysis of Options:** * **Option B (Correct):** Leaving the cap for 8 hours ensures that no viable sperm enter the uterus. Note that while it must stay for 8 hours, it should not be left in place for more than 48 hours due to the risk of Toxic Shock Syndrome (TSS). * **Option A & D (Incorrect):** Leaving the device for the entire cycle or until menstruation is dangerous. Prolonged retention promotes bacterial overgrowth (Staphylococcus aureus), significantly increasing the risk of TSS and vaginal irritation. * **Option C (Incorrect):** Immediate removal allows live sperm to enter the cervix. Furthermore, vaginal douching is generally discouraged as it can push sperm further into the canal and disrupt the normal vaginal flora. **High-Yield Facts for NEET-PG:** * **Comparison:** Unlike the diaphragm, the cervical cap provides protection for multiple acts of intercourse without needing additional spermicide application (though it must be checked for position). * **Contraindications:** Not recommended in women with a history of TSS, abnormal Pap smears, or pelvic inflammatory disease (PID). * **Failure Rate:** Higher in multiparous women compared to nulliparous women due to changes in cervical shape after childbirth. * **Key Timing:** Minimum 6–8 hours post-coitus; Maximum 48 hours total wear time.

Question 257: Which of the following is NOT a characteristic feature of an ideal IUCD candidate?

A. Has borne at least two children (Correct Answer)
B. Has no history of pelvic disease
C. Has normal menstrual periods
D. Is willing to check the IUCD tail

Explanation: ### Explanation The Intrauterine Contraceptive Device (IUCD) is a highly effective long-acting reversible contraceptive (LARC). To minimize complications like expulsion, infection, or bleeding, the World Health Organization (WHO) and standard textbooks define specific criteria for an "ideal candidate." **Why Option A is the Correct Answer:** An ideal candidate is defined as a woman who has borne **at least one child** (multiparous). While having two children is acceptable, it is not a *requirement* to be an ideal candidate. The medical rationale for preferring multiparous women is that the uterine cavity is more spacious and the cervical canal is more dilated, which reduces the risk of pain during insertion and subsequent expulsion. However, modern guidelines (MEC criteria) state that IUCDs can be used in nulliparous women, though they are not considered the "ideal" candidates due to higher discontinuation rates from pain. **Analysis of Incorrect Options:** * **Option B (No history of pelvic disease):** This is a core requirement. A history of Pelvic Inflammatory Disease (PID) or current STIs increases the risk of post-insertion infection (Actinomycosis or flare-ups). * **Option C (Normal menstrual periods):** IUCDs (especially Copper-T) can increase menstrual blood flow and cramping. Therefore, a woman with pre-existing menorrhagia or dysmenorrhea is not an ideal candidate for a copper IUCD. * **Option D (Willing to check the tail):** The user must be motivated to periodically check for the presence of the string (tail) to ensure the device has not been expelled unnoticed. **High-Yield Clinical Pearls for NEET-PG:** * **Ideal Age:** Usually between 25–35 years. * **Most Common Side Effect:** Excessive menstrual bleeding (Menorrhagia). * **Most Common Reason for Removal:** Pain and bleeding. * **Mechanism of Action:** Primarily a **foreign body reaction** causing biochemical changes in the endometrium and a spermicidal effect (Copper ions). * **Contraindication:** Undiagnosed vaginal bleeding and distorted uterine cavity (e.g., large fibroids).

Question 258: Which of the following is NOT a contraindication for insertion of an IUCD?

A. PID
B. Presence of fibroids
C. Suspected pregnancy
D. Cervical discharge (Correct Answer)

Explanation: **Explanation:** The correct answer is **Cervical discharge**. In clinical practice, the presence of physiological cervical discharge is not a contraindication for IUCD insertion. However, if the discharge is purulent and associated with an active infection (like cervicitis or PID), insertion should be delayed. According to WHO Medical Eligibility Criteria (MEC), a history of non-purulent discharge does not preclude IUCD use. **Analysis of Options:** * **PID (Pelvic Inflammatory Disease):** This is a **Category 4 contraindication** (absolute). Inserting an IUCD during active PID can exacerbate the infection and lead to complications like tubo-ovarian abscess or infertility. * **Presence of fibroids:** While not all fibroids are contraindications, those that **distort the uterine cavity** (e.g., submucosal fibroids) are a contraindication because they prevent proper placement, increase the risk of expulsion, and may cause heavy bleeding. * **Suspected pregnancy:** This is an absolute contraindication. Insertion during pregnancy can lead to septic abortion or miscarriage. **High-Yield Clinical Pearls for NEET-PG:** * **WHO MEC Category 4 (Absolute Contraindications):** Unexplained vaginal bleeding, current PID, current STI (cervicitis), gestational trophoblastic disease, and copper allergy (for Cu-T). * **Ideal time for insertion:** Within 10 days of the onset of menstruation (to ensure the patient is not pregnant and the cervical os is slightly dilated). * **Post-placental insertion:** Within 48 hours of delivery (though risk of expulsion is higher). * **Most common side effect:** Bleeding (menorrhagia) is the most common reason for removal. Pain is the second most common.

Question 259: In Cu T-200, what does the number denote?

A. Surface area (Correct Answer)
B. Weight in micrograms
C. Weight in milligrams
D. Effective half-life in weeks

Explanation: In the nomenclature of Intrauterine Contraceptive Devices (IUCDs) like **Cu T-200**, the numerical value refers specifically to the **surface area of the copper wire** (in square millimeters) wrapped around the vertical stem of the device. ### **Explanation of Options:** * **A. Surface Area (Correct):** The efficacy of a copper IUCD is directly proportional to the surface area of copper exposed to the uterine environment. In Cu T-200, there are **200 mm²** of copper. This surface area facilitates the release of copper ions, which act as a spermicide by inhibiting sperm motility and viability. * **B & C. Weight:** While the copper wire has a specific weight, the naming convention is standardized by area, not mass. For example, the Cu T-380A has 380 mm² of copper, which provides higher efficacy and a longer lifespan than the 200 model. * **D. Effective Half-life:** The number does not represent time. The "life" of the device is determined by the rate of copper fragmentation; Cu T-200 is typically effective for **3 years**, whereas Cu T-380A is effective for **10 years**. ### **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Primarily **pre-fertilization** (spermicidal). It causes a sterile inflammatory response in the endometrium, increasing prostaglandins and white blood cells. * **Cu T-380A (ParaGard):** The "A" signifies that the copper is also present on the horizontal arms (sleeves), increasing the surface area to 380 mm². It is currently the "Gold Standard" IUCD. * **Ideal Candidate:** Multiparous women in a stable monogamous relationship. * **Most Common Side Effect:** Excessive menstrual bleeding (menorrhagia). * **Most Common Reason for Removal:** Pain and bleeding.

Question 260: In which of the following situations is it preferable NOT to insert an IUCD?

A. Postmenstrual
B. Emergency postcoital
C. Six weeks after delivery
D. Immediately following a mid-trimester abortion (Correct Answer)

Explanation: ### Explanation The correct answer is **D. Immediately following a mid-trimester abortion.** **1. Why Option D is Correct:** The risk of **expulsion** and **perforation** is significantly higher when an Intrauterine Contraceptive Device (IUCD) is inserted immediately after a mid-trimester (second trimester) abortion. During this period, the uterus is large, soft, and thin-walled. Furthermore, the cervix is dilated, making it easier for the device to be expelled as the uterus undergoes involution. Standard practice recommends waiting for **6 weeks** (post-involution) before insertion in such cases. **2. Analysis of Incorrect Options:** * **A. Postmenstrual:** This is the **ideal time** for insertion. The cervix is slightly open, the endometrium is thin (minimizing trauma/bleeding), and it confirms the patient is not pregnant. * **B. Emergency postcoital:** A Copper-T is the most effective method of emergency contraception if inserted within **5 days (120 hours)** of unprotected intercourse. * **C. Six weeks after delivery:** This is known as **Interval Insertion**. By 6 weeks, the uterus has returned to its normal size (involution complete), making it a safe and standard time for insertion. **3. High-Yield Clinical Pearls for NEET-PG:** * **PPIUCD (Postpartum IUCD):** Can be inserted within **48 hours** of delivery. If not done within 48 hours, wait for 6 weeks (due to high expulsion risk between 48 hours and 6 weeks). * **Post-Abortion:** IUCD can be inserted immediately after a **first-trimester** abortion (MTP/spontaneous), but should be delayed after a second-trimester abortion. * **Most Common Side Effect:** Bleeding (Menorrhagia). * **Most Common Reason for Removal:** Bleeding/Pain. * **Absolute Contraindication:** Undiagnosed vaginal bleeding, current PID, or suspected pregnancy.

Practice by Chapter

Natural Family Planning Methods

Practice Questions

Barrier Methods

Practice Questions

Hormonal Contraceptives

Practice Questions

Intrauterine Devices

Practice Questions

Emergency Contraception

Practice Questions

Permanent Contraception Methods

Practice Questions

Contraception in Special Populations

Practice Questions

Contraceptive Counseling

Practice Questions

Side Effects and Complications of Contraceptives

Practice Questions

Future Contraceptive Technologies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free